Publications

BibTex format

@article{Wachter:2020:10.1002/ehf2.12694,
author = {Wachter, R and Shah, SJ and Cowie, MR and Szecsödy, P and Shi, V and Ibram, G and Zhao, Z and Gong, J and Klebs, S and Pieske, B},
doi = {10.1002/ehf2.12694},
journal = {ESC Heart Failure},
pages = {856--864},
title = {Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial},
url = {http://dx.doi.org/10.1002/ehf2.12694},
volume = {7},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - AIMS: Although the effect of the angiotensin receptor blocker neprilysin inhibitor (ARNI) sacubitril/valsartan on heart failure (HF) hospitalizations and cardiovascular death has been evaluated, its effects on functional capacity in patients with HF and ejection fraction (EF) >40% has yet to be determined. In addition, no prior studies have compared sacubitril/valsartan with angiotensin-converting enzyme inhibitor therapy. We sought to compare the effect of ARNI to background-medication-based individualized comparators (BMICs) on N-terminal pro-B-type natriuretic peptide (NT-proBNP), functional capacity [6 min walk distance (6MWD)], symptoms, and quality of life [Kansas City Cardiomyopathy Questionnaire (KCCQ)] in patients with HF and EF >40% in a randomized clinical trial. METHODS: PARALLAX is a prospective, randomized, controlled, double-blind multicentre clinical trial in patients with chronic symptomatic HF with EF >40%, New York Heart Association (NYHA) class II-IV symptoms, elevated natriuretic peptides, and evidence of structural heart disease. Eligible patients are randomized to sacubitril/valsartan vs. BMIC for cardiovascular and related co-morbidities. BMIC includes (i) enalapril, (ii) valsartan, and (iii) placebo depending on the type of medical therapy prior to enrolment. The primary endpoints are the change in plasma NT-proBNP concentration from baseline to 12 weeks and the change from baseline in 6MWD distance at 24 weeks. The secondary endpoints assess quality of life and symptom burden. CONCLUSIONS: PARALLAX will determine if sacubitril/valsartan compared with standard medical therapy for co-morbidities improves NT-proBNP levels, exercise capacity, quality of life, and symptom burden in HF patients with EF >40%.
AU  - Wachter,R
AU  - Shah,SJ
AU  - Cowie,MR
AU  - Szecsödy,P
AU  - Shi,V
AU  - Ibram,G
AU  - Zhao,Z
AU  - Gong,J
AU  - Klebs,S
AU  - Pieske,B
DO  - 10.1002/ehf2.12694
EP  - 864
PY  - 2020///
SN  - 2055-5822
SP  - 856
TI  - Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
T2  - ESC Heart Failure
UR  - http://dx.doi.org/10.1002/ehf2.12694
UR  - https://www.ncbi.nlm.nih.gov/pubmed/32297449
UR  - http://hdl.handle.net/10044/1/78861
VL  - 7
ER  -

Download

ProfessorMartinCowie

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)